EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY

Experimental and Clinical Psychopharmacology seeks to promote the discipline of psychopharmacology in its fullest diversity. Psychopharmacology necessarily involves behavioral change, psychological processes, or their physiological substrates as one central variable and psychopharmacological agents as a second central variable. Such agents will include drugs, medications, and chemicals encountered in the workplace or environment. One goal of the journal is to foster basic research and the development of theory in psychopharmacology. Another is to encourage the integration of basic and applied research, the development of better treatments for drug abuse, and more effective pharmacotherapeutics. To this end, the journal publishes original empirical research involving animals or humans that spans (a) behavioral pharmacology research on social, behavioral, cognitive, emotional, physiological, and neurochemical toxicity; (b) descriptive and experimental studies of drug abuse, including its etiology, progression, adverse effects, and behavioral and pharmacological treatment; and (c) controlled clinical trials that, in addition to improving the effectiveness, range, or depth of application, will increase our understanding of psychological functions or their drug modulation. The journal also publishes theoretical and integrative analyses and reviews that promote our understanding and further systematic research in psychopharmacology. The journal also publishes papers in two other sections, Innovations and Remarks. Innovations is an occasional section that will highlight papers that establish a novel method, a novel result, a novel measure, or a new theory. Commentary may be solicited to address the nature of the innovation and to provide contrasting views. Remarks is another occasional section. The purpose of "remarks" is for brief commentary about important aspects of the field that have not been previously addressed or considered. Remarks could address either empirical or theoretical issues. Remarks are expected to be erudite, integrative, substantive, and thoughtful. Although case studies are not appropriate, occasional small sample experiments with special populations may be considered. The journal is intended to be informative and useful to both basic and applied researchers and to practitioners operating in varied settings. Experimental and Clinical Psychopharmacology seeks to be the vehicle for the best research ideas and for integrating pharmacology and behavior.

EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY期刊中文简介

实验和临床精神药理学旨在促进精神药理学学科的最大多样性。心理药理学必然涉及行为变化、心理过程或其生理底物作为一个中心变量，心理药理学药物作为第二个中心变量。这些药剂包括在工作场所或环境中遇到的药物、药物和化学品。该杂志的一个目标是促进基础研究和心理药理学理论的发展。另一个是鼓励基础研究和应用研究相结合，开发更好的药物滥用治疗方法，以及更有效的药物治疗。为此，该杂志发表了涉及动物或人类的原始实验研究，涵盖（a）社会、行为、认知、情感、生理和神经化学毒性的行为药理学研究；（b）药物滥用的描述性和实验研究，包括其病因、进展、不良反应和行为和药物治疗；（c）对照临床试验，除了提高有效性、应用范围或深度外，还将增加我们对心理功能或药物调节的理解。该杂志还发表了理论和综合分析和评论，以促进我们的理解和进一步的心理药理学系统研究。该杂志还出版了其他两个部分的论文：创新和评论。创新是一个偶然的部分，它将强调建立一种新方法、新结果、新措施或新理论的论文。可以征求评论来说明创新的性质，并提供对比意见。评论是另一个偶然的部分。“评论”的目的是对该领域的重要方面进行简短的评论，而这些方面此前尚未得到讨论或考虑。评论可以解决经验或理论问题。预计发言将是博学的、综合的、实质性的和深思熟虑的。虽然案例研究不合适，但偶尔也可以考虑对特殊人群进行小样本实验。该杂志旨在为基础和应用研究人员以及在不同环境下工作的从业者提供信息和有用。实验和临床精神药理学寻求成为最佳研究思想和整合药理学和行为的载体。